Literature DB >> 25527506

Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.

Suk Hyung Lee1, Daniel Johnson1, Richard Luong2, Zijie Sun3.   

Abstract

Both androgen action and PI3K medicated signaling pathways have been implicated in prostate tumorigenesis. Our androgen receptor (AR) conditional transgenic mice developed murine prostatic intraepithelial neoplasia (mPIN) and prostatic adenocarcinoma lesions recapitulating human prostate cancer development and progression. Role of transgenic AR contributing to malignancy was demonstrated by high degree of transgenic AR expression in atypical and tumor cells in mPIN as well as prostatic adenocarcinoma lesions of the transgenic mice, but not in adjacent normal tissue. Interestingly, reduced PI3K/Akt activation also appeared in these mouse atypical and tumor cells, suggesting an interaction between androgen and PI3K/AKT pathways. In this study, we further investigated this interaction. We showed that the androgen depletion or knockdown of AR expression results in elevated levels of active phosphorylated AKT in prostate cancer cells. Castration of conditional Pten knock-out mice showed increased Akt, phosphorylated Akt, and pS6 expression in the mouse prostate. Using a series of newly generated Ar reporter and Pten knock-out compound mice, we showed that Pten loss directly represses endogenous Ar expression in prostatic epithelial cells. Moreover, Pten loss and PI3K/Akt activation reduced Ar-mediated transcription in purified Pten-null cells. This study provides novel evidence demonstrating interplay between androgen and PI3K pathways, as well as introduces unique and relevant mouse models for further studies of PI3K and AR pathways in the context of prostate tumorigenesis.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Akt PKB; Androgen; Androgen Receptor; Mouse; Phosphatidylinositide 3-Kinase (PI 3-kinase); Prostate Cancer

Mesh:

Substances:

Year:  2014        PMID: 25527506      PMCID: PMC4317037          DOI: 10.1074/jbc.M114.607846

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

3.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Authors:  Xiaoqian Ma; Angelique C Ziel-van der Made; Binha Autar; Hetty A van der Korput; Marcel Vermeij; Petra van Duijn; Kitty B Cleutjens; Ronald de Krijger; Paul Krimpenfort; Anton Berns; Theo H van der Kwast; Jan Trapman
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.

Authors:  X Wu; J Wu; J Huang; W C Powell; J Zhang; R J Matusik; F O Sangiorgi; R E Maxson; H M Sucov; P Roy-Burman
Journal:  Mech Dev       Date:  2001-03       Impact factor: 1.882

5.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 6.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

Authors:  P Cairns; K Okami; S Halachmi; N Halachmi; M Esteller; J G Herman; J Jen; W B Isaacs; G S Bova; D Sidransky
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

Review 8.  Mutations of the human PTEN gene.

Authors:  D Bonneau; M Longy
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

9.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

Authors:  H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S Bova
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

10.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more
  33 in total

1.  Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.

Authors:  Chenchen He; Shaofeng Duan; Liang Dong; Yifen Wang; Qingting Hu; Chunjing Liu; Marcus L Forrest; Jeffrey M Holzbeierlein; Suxia Han; Benyi Li
Journal:  Prostate       Date:  2017-06-20       Impact factor: 4.104

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

Authors:  Marco A De Velasco; Yurie Kura; Kazuko Sakai; Yuji Hatanaka; Barry R Davies; Hayley Campbell; Stephanie Klein; Youngsoo Kim; A Robert MacLeod; Koichi Sugimoto; Kazuhiro Yoshikawa; Kazuto Nishio; Hirotsugu Uemura
Journal:  JCI Insight       Date:  2019-09-05

4.  Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.

Authors:  Remi Adelaiye-Ogala; Nur P Damayanti; Ashley R Orillion; Sreevani Arisa; Sreenivasulu Chintala; Mark A Titus; Chinghai Kao; Roberto Pili
Journal:  Cancer Res       Date:  2018-03-23       Impact factor: 12.701

Review 5.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

6.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.

Authors:  Mirjam Blattner; Deli Liu; Brian D Robinson; Dennis Huang; Anton Poliakov; Dong Gao; Srilakshmi Nataraj; Lesa D Deonarine; Michael A Augello; Verena Sailer; Lalit Ponnala; Michael Ittmann; Arul M Chinnaiyan; Andrea Sboner; Yu Chen; Mark A Rubin; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

Review 7.  PTEN-opathies: from biological insights to evidence-based precision medicine.

Authors:  Lamis Yehia; Joanne Ngeow; Charis Eng
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

8.  In silico analysis of the transportome in human pancreatic ductal adenocarcinoma.

Authors:  A Zaccagnino; C Pilarsky; D Tawfik; S Sebens; A Trauzold; I Novak; A Schwab; H Kalthoff
Journal:  Eur Biophys J       Date:  2016-09-21       Impact factor: 1.733

Review 9.  mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.

Authors:  Cara M Statz; Sara E Patterson; Susan M Mockus
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 10.  Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.

Authors:  Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.